Reactions Weekly

, Volume 1673, Issue 1, pp 215–215 | Cite as

Ipilimumab/nivolumab

Various toxicities: 5 case reports
Case report
  • 35 Downloads

Reference

  1. Le Burel S, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. European Journal of Cancer 82: 34-44, Sep 2017. Available from: URL: http://doi.org/10.1016/j.ejca.2017.05.032 - FranceCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Personalised recommendations